New combo therapy aims to tackle tough prostate cancer
NCT ID NCT06499870
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether adding two hormone-blocking drugs, relugolix and enzalutamide, to standard radiation therapy can better control very-high-risk prostate cancer. About 50 men will receive the combination for 18 months. The main goal is to see if it lowers the chance of cancer returning after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Relugolix and enzalutamide (hormone therapy drugs) plus radiation therapy
What this could lead to
If successful, this combination could offer a more effective treatment option for men with very-high-risk prostate cancer, potentially reducing recurrence and improving survival.
What could go wrong
This is an early phase II trial with only 50 participants, so results may not apply to everyone. Hormone therapy can cause side effects like hot flashes, fatigue, and sexual dysfunction.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••